Estimate of Costs Associated With Atrial Fibrillation Treatment With Rivaroxaban Versus Vitamin K Antagonists
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 249
- 主要终点
- Presence of stroke
研究概览
简要总结
The main objective of this project is to evaluate savings in direct costs as regards the use of rivaroxaban versus vitamin K antagonists (VKAs) in routine clinical practice using data from three cohorts of patients receiving VKAs or rivaroxaban in Spain, including the time in therapeutic range (TTR) values of the same and the incidence of events in the first year following diagnosis.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Older than 18 years
- •Diagnosis of non-valvular AF (ICD code 427.31)
- •Pharmacological treatment with VKAs or rivaroxaban following diagnosis
排除标准
- 未提供
研究组 & 干预措施
Treatment group with Rivaroxaban
Patients treated with Rivaroxaban
干预措施: Rivaroxaban (Xarelto, BAY59-7939) (Drug)
Control group with VKAs
Patients treated with VKAs. This control group will be subsequently divided based on the TTR value in the last 6 months (below 65% and above 65%).
干预措施: Vitamin K antagonists (VKAs) (Drug)
结局指标
主要结局
Presence of stroke
时间窗: 12 months
Presence of stroke prior and subsequent to treatment
Active substance received
时间窗: 12 months
Rivaroxaban or VKAs (Acenocoumarol and Warfarin)
Time in therapeutic range (TTR) values in the last 6 months
时间窗: 6 months
次要结局
- Frequency of the prescribed treatment (in hours)(12 months)
- Date of stroke(12 months)
- Duration of treatment (in days)(12 months)
- Type of stroke(12 months)
- Dose of the prescribed treatment(12 months)